Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985865 | 0.76 | ALDH1A1 (0.48) | ALDH1A1TP53TDP1 | |
| SCHEMBL15107889 | 0.75 | TP53 (0.39) | ALDH1A1TP53TDP1HDAC8 | |
| SCHEMBL27781372 | 0.74 | AHR (0.55) | ALDH1A1TP53TDP1AHR | |
| SCHEMBL16957329 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TP53TDP1HDAC8 | |
| SCHEMBL1122678 | 0.74 | ALDH1A1 (0.45) | ALDH1A1TP53TDP1AHR | |
| SCHEMBL4576166 | 0.71 | TRPA1 (0.48) | ALDH1A1TDP1 | |
| SCHEMBL21313018 | 0.71 | ALOX15 (0.31) | — | |
| SCHEMBL11985992 | 0.71 | ALDH1A1 (0.47) | ALDH1A1TP53AHR | |
| SCHEMBL10738398 | 0.70 | ALDH1A1 (0.50) | ALDH1A1TP53TDP1 | |
| SCHEMBL16960668 | 0.70 | ALDH1A1 (0.36) | ALDH1A1TP53TDP1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 1560/4885TP53 1686/4885TDP1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.